Abstract: Venomous snakebite is considered the single most important cause of human injury from venomous animals worldwide. Coagulopathy is one of the commonest important systemic clinical syndromes and can be complicated by serious and life-threatening haemorrhage. Venom-induced consumption coagulopathy (VICC) is the commonest coagulopathy resulting from snakebite and occurs in envenoming by Viperid snakes, certain elapids, including Australian elapids, and a few Colubrid (rear fang) snakes. Procoagulant toxins activate the clotting pathway, causing a broad range of factor deficiencies depending on the particular procoagulant toxin in the snake venom. Diagnosis and monitoring of coagulopathy is problematic, particularly in resource-poor countries where further research is required to develop more reliable, cheap clotting tests. MEDLINE and EMBASE up to September 2013 were searched to identify clinical studies of snake envenoming with VICC. The UniPort database was searched for coagulant snake toxins. Despite preclinical studies demonstrating antivenom binding toxins (efficacy), there was less evidence to support clinical effectiveness of antivenom for VICC. There were no placebo-controlled trials of antivenom for VICC. There were 25 randomised comparative trials of antivenom for VICC, which compared two different antivenoms (ten studies), three different antivenoms (four), two or three different doses or repeat doses of antivenom (five), heparin treatment and antivenom (five), and intravenous immunoglobulin treatment and antivenom (one). There were 13 studies that compared two groups in which there was no randomisation, including studies with historical controls. There have been numerous observational studies of antivenom in VICC but with no comparison group. Most of the controlled trials were small, did not use the same method for assessing coagulopathy, varied the dose of antivenom, and did not provide complete details of the study design (primary outcomes, randomisation, and allocation concealment). Non-randomised trials including comparison groups without antivenom showed that antivenom was effective for some snakes (e.g., Echis), but not others (e.g., Australasian elapids). Antivenom is the major treatment for VICC, but there is currently little high-quality evidence to support effectiveness. Antivenom is not risk free, and adverse reactions can be quite common and potentially severe. Studies of heparin did not demonstrate it improved outcomes in VICC. Fresh frozen plasma appeared to speed the recovery of coagulopathy and should be considered in bleeding patients.

Introduction
Venomous snakebite is considered to be the single most important cause of human injury from any kind of venomous or poisonous animal worldwide. Envenoming and deaths resulting from snakebite are a particularly important public health problem in the tropical world, with the highest burden in rural areas of South Asia, Southeast Asia, and sub-Saharan Africa [1]. Coagulopathy is the commonest important, systemic clinical syndrome caused by snake envenoming in the world, and venom-induced consumption coagulopathy (VICC) is the most clinically important coagulopathy, because it can be complicated by serious and life-threatening haemorrhage [2].

Methods
We searched MEDLINE from 1946 and EMBASE from 1947 to September 2013 and included any clinical studies of snake envenoming with VICC which provided information on treatment, including antivenom. The following keywords were used: “snakebite”, “snake envenoming/envenomation”, “coagulopathy”, “bleeding”, “haemorrhage”, “antivenom”, “heparin”, and “treatment”. Reference lists of identified articles were searched to find additional publications. Only articles in English were reviewed. The UniPort database (www.uniport.org) was also used for information on isolated toxins from snake venoms with coagulant actions. We identified a total of 1,353 studies of which 95 were included for review. There were 25 randomised comparative trials, 13 non-randomised comparative trials, and a large number of observational clinical studies which discussed the effectiveness of treatments for VICC.

Citation: Maduwage K, Isbister GK (2014) Current Treatment for Venom-Induced Consumption Coagulopathy Resulting from Snakebite. PLoS Negl Trop Dis 8(10): e3220. doi:10.1371/journal.pntd.0003220

Editor: Janaka de Silva, Faculty of Medicine, University of Kelaniya, Sri Lanka

Published October 23, 2014

Copyright: © 2014 Maduwage, Isbister. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: GKI is supported by an National Health and Medical Research Council (NHMRC) Senior Research Fellowship (1061041) and the review was partly funded by an NHMRC Project Grant ID 631073. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* Email: geoff.isbister@gmail.com
Venom-Induced Consumption Coagulopathy (VICC)

Various studies have been used to refer to the consumption coagulopathy following snake envenoming, including disseminated intravascular coagulation (DIC), defibrination syndrome, and procoagulant coagulopathy [3]. More recently, the term “venom-induced consumption coagulopathy” has been introduced because it provides a more general description of the coagulopathy [4]. VICC can occur in envenoming by Viperid snakes, certain elapids, including Australian elapids [2], and a few Colubrid (rear fang) snakes [5]. A list of the major snake species that cause VICC is included in Table 1.

VICC results from the activation of the clotting pathway by procoagulant toxins in the venom. The snake venom components that act on the coagulation system are classified according to the part of the coagulation pathway where they act and include factor V activators, factor X activators, prothrombin activators, and thrombin-like enzymes (TLEs) or fibrinogenases (Figure 1) [6]. The severity, duration, and type of consumption coagulopathy differ depending on the type of procoagulant toxin. Table 1 provides more detailed information on the clotting factor deficiencies in VICC for different snake groups. Almost all of these toxins cause activation of one or more clotting factors and lead to low or undetectable concentrations of fibrinogen following envenoming [2]. Thrombin-like enzymes or fibrinogenases generally cleave either the α-chain or the β-chain of fibrinogen to give fibrinopeptide A or B, which results in the consumption of fibrinogen without forming fibrin [4]. Therefore these toxins do not strictly activate the entire clotting pathway, but result in low or undetectable fibrinogen concentration, often with normal levels of the other clotting factors. In contrast, toxins that act higher up the clotting pathway, such as factor X activators or prothrombin activators, result in multiple factor deficiencies such as those occurring with Australian elapids [2], Russell’s viper [7], and Echis spp. [8].

The diagnosis and monitoring of VICC requires coagulation studies and clotting times [9]. The majority of these tests are rarely available where most cases of snake envenoming occur. Internationally, the most commonly used test is the 20-minute whole blood clotting test (WBCT20) [8,10–15]. However, the reliability of the WBCT20 as a diagnostic test has come into question for the diagnosis of Russell’s viper envenoming [16]. There is no standardisation of the WBCT, including the duration of the test, the type of glass tube used for the test, and the procedure. The duration of the WBCT ranges from 10 minutes [17] in some studies to 30 minutes in others [18–20]. In other parts of the world more routine clotting tests, such as the prothrombin time (PT; international normalised ratio, INR), activated partial thromboplastin time (aPTT), and thrombin clotting time (TCT), are used [2,21–23].

Many patients with VICC may exhibit minimal clinical features other than bleeding from the bite site or cannula site. However, some patients develop bleeding from the gums, gastrointestinal tract bleeding (clinically manifesting as melena or haematemesis), and haematuria [7]. This is usually caused by snakes with venoms that also contain haemorrhagins such as Echis spp. [22,24] and Bothrops spp. [25]. More severe bleeding includes intracranial haemorrhage, which is often fatal, and bleeding associated with trauma. Bleeding into the pituitary gland has also been reported following viper envenoming and produces subtle or delayed clinical signs compatible with Sheehan’s syndrome [26,27].

This review will focus on the effectiveness of various treatments for VICC based on the evidence from clinical studies, but will not cover venom-induced thrombocytopenia, [28,29], snakebite-associated thrombocytopenia, [2], or antiocoagulant coagulopathy [30].

Antivenom

Antivenoms and their mechanism of action

Antivenom is the recommended standard treatment for snake envenoming. Antivenoms consist of polyclonal antibodies to the toxins in snake venoms [31]. They may be whole immunoglobulins (IgG) or fractionated IgG, either Fab’ or Fab [32]. The antibodies are produced in animals, including horse, sheep, goats, and rabbits. The animals are injected with the snake venom so that they mount an immune response and produce antibodies to that venom [33,34]. The polyclonal nature of antivenom means that they are able to neutralise multiple venom components [32]. Monovalent antivenoms are raised against one species of snakes, while polyvalent snake antivenoms are produced by immunizing with venoms from more than one species of snake [33].

The efficacy of antivenom is best defined as its ability to bind venom components or toxins [35], while the effectiveness of antivenom is its ability to prevent or reverse the effects of envenoming in humans. There are a number of proposed mechanisms by which the binding of antivenom to venom results in prevention or reversal of envenoming. Antivenom can potentially block the active site of a toxin or bind to a toxin to prevent it interacting with its substrate (steric hindrance) to neutralise the toxin. Antivenom-venom complex formation in the central compartment may prevent the distribution of toxins to the target tissues (e.g., nervous system) or cause the redistribution of toxins from their target tissues back to the vascular compartment [32,36–38]. Finally, antivenom can increase the elimination of toxins from the circulation and body. In the case of VICC, the toxins act in the central compartment, so antivenom must either bind to the toxins in the blood, and therefore prevent the action of the toxins, or increase the elimination of toxins.

Numerous studies have demonstrated that antivenom can bind to procoagulant toxins and prevent their effects in vitro if the antivenom and venom are pre-mixed [39–43]. Despite antivenom being efficacious and binding to the multiple toxins in the venom, there are a number of reasons that it may not be effective [35]. The most important being that irreversible toxic effects cannot be reversed by antivenom binding to toxins after the damage has occurred, such as clotting factor deficiencies resulting from VICC [9]. For antivenom to be effective against such irreversible effects, it must be administered early, so it can bind with toxins before they distribute to their target sites and cause irreversible toxicity.

Procoagulant toxins act in the central compartment (circulation), making their onset of action relatively rapid. Once they have activated the clotting pathway and clotting factors have been consumed, this process is irreversible until further clotting factors can be re-synthesised. Antivenom can only be effective in preventing the onset of VICC if it binds the procoagulant toxins prior to the clotting pathway being activated. A semi-mechanistic systems model of the coagulation cascade has been used to simulate the effects of Australasian elapid venoms on the clotting pathway and shows that antivenom needs to be administered within 15 to 30 minutes to prevent or even partially prevent VICC occurring [44–46]. However, the duration of VICC can be days for some snakes such as Echis spp., so the administration of antivenom will potentially bind the active procoagulant toxins, allowing the clotting factors to recover. Antivenom will therefore be clinically effective in shortening the duration of VICC and reducing the risk of bleeding.
Table 1. Summary of snakes known to cause venom-induced consumption coagulopathy, the procoagulant toxin, and the factor deficiencies that have been reported (with permission from WikiToxin).

| Snake species                   | Common name           | Distribution | Procoagulant Toxins | VICC Testing | Factor Deficiencies | References             |
|---------------------------------|-----------------------|--------------|---------------------|--------------|---------------------|------------------------|
| Daboia russelli                 | Russell’s viper       | Asia         | FX, FV activators   | WBT20, CT, fibrinogen, clotting factor studies | Fibrinogen, FV, FX    | Phillips [7], Isbister [16] |
| Daboia russelli siamensis       | Eastern Russell’s viper, Siamese Russell’s viper | Asia         | FX, FV activators   | PT, non-clotting blood | Fibrinogen, FV, FX    | Than [88], Tin Na [78]     |
| Hypnale hypnale                 | Hump-nosed pit vipers | Asia         | Unknown? TLE        | WBT20, PT, aPTT, clotting factor studies, D-Dimer | Fibrinogen, FV       | Maduwage [13]             |
| Echis carinatus                 | Saw scaled viper      | Asia         |                     | WBT20        | NR                  | Kularatne [11]          |
| Calloselasma rhodostoma         | Malayan pit viper     | Asia         | TLE                 | VCT >30 minutes, fibrinogen, FDP, clotting factor studies | Fibrinogen           | Kulapongs [89], Warrell [70] |
| Trimeresurus albolabris         | White-lipped green pit viper | Asia         | TLE                 | Fibrinogen, FDP, fibrinopeptide A, plasminogen | Fibrinogen           | Hutton [90], Rojnuckarin [91] |
| Trimeresurus macrops            | Large-eyed pitviper (green pitviper) | Asia         | TLE                 | Fibrinogen, FDP, fibrinopeptide A, plasminogen | Fibrinogen           | Rojnuckarin [91]          |
| Trimeresurus stejnegeri         | Bamboo pitviper, Chinese tree viper | Asia         | TLE, plasminogen activator | Fibrinogen, FDP, AT-III | Fibrinogen | Li [92] |
| Rhabdophis subminiatus          | Red-necked keelback   | Asia         |                     | ?            | Fibrinogen, FDP     | Fibrinogen Li [92]      |
| Rhabdophis tigrinus             | Tiger keelback        | Asia         |                     | PT, aPTT, Fibrinogen, FDP | Fibrinogen       | Mori [93]                |
| Pseudonaja spp.                 | Brown snake           | Australia    | PTA                 | PT, aPTT, clotting factor studies, D-dimer | Fibrinogen, FIL, FV, FVIII | Isbister [3]            |
| Notechis scutatus               | Tiger snake           | Australia    | PTA                 | PT, aPTT, clotting factor studies, D-dimer | Fibrinogen, FIL, FV, FVIII | Isbister [3]            |
| Tropidechis carinatus           | Rough-scaled snake    | Australia    | PTA                 | PT, aPTT, clotting factor studies, D-dimer | Fibrinogen, FIL, FV, FVIII | Isbister [3]            |
| Hoplocephalus spp.              | Broad-headed snakes   | Australia    | PTA                 | PT, aPTT, clotting factor studies, D-dimer | Fibrinogen, FIL, FV, FVIII | Isbister [3]            |
| Oxyuranus scutellatus           | Coastal taipan        | Australasia  | PTA                 | PT, aPTT, clotting factor studies, D-dimer | Fibrinogen, FIL, FV, FVIII | Isbister [3], Laloo [94] |
| Bothrops atrax                  | Common Lancehead      | South America| TLE, FX, FV, activators | PT, aPTT, D-dimer, FDP | Fibrinogen       | Pardal [60]             |
| Bothrops asper                   | Lancehead, Terciopelo | South America| TLE, PTA            | PT, aPTT, clotting factor studies, D-dimer | Fibrinogen, FIL, FV | Barrantes [95], Otero-Patino [59] |
| Bothrops jararaca                | Jaranaca              | South America| TLE, PT, FX activator| Fibrinogen, clotting factor studies | Fibrinogen, FIL, FV, FVIII | Kamiguti [96], Jorge [71] |
| Lachesis spp.                   | Bushmasters           | Central America| TLE                 | Fibrinogen, D-dimer, α2-antiplasmin, FDP | Fibrinogen       | Pardal [60]             |
| Crotalus durissus               | South American rattlesnake | Central and South America | TLE | PT, aPTT, clotting factor studies, D-dimer | Fibrinogen, FIL, FV | Sano-Martín [97], Kamiguti [98] |
| Crotalus atrox                   | Western diamondback rattlesnake | North America | TLE | PT, aPTT, Fibrinogen | Fibrinogen | Budzynski [99]          |
| Crotalus adamanteus             | Eastern diamondback rattlesnake | North America | TLE | PT, aPTT, fibrinogen, D-dimer, FDP, antiplasmin III | Fibrinogen, D-dimer | Kitchens [100]          |
| Crotalus molossus molossus      | Black-tailed rattlesnake | North America | ? TLE | PT, fibrinogen, FDP | Fibrinogen | Hardy [101]              |
| Crotalus horridus               | Timber rattlesnake     | North America| TLE                 | Fibrinogen, FDP | Fibrinogen | Hasiba [102]            |
| Crotalus helleri                | Southern Pacific rattlesnake | North America | TLE | PT, fibrinogen | Fibrinogen | Bush [103]              |
| Vipera aspis                    | European asp/Asp viper | Europe       | FX activator        | PT, aPTT, fibrinogen, D-dimer | Fibrinogen | Boels [104], Petite [105] |
| Vipera berus                    | Common European viper  | Europe       |                     | PT, aPTT, fibrinogen, D-dimer | Fibrinogen | Boels [104]              |
| Vipera ammodytes ammodytes      | Horned viper           | Europe       |                     | PT, aPTT, fibrinogen, D-dimer | Fibrinogen | Luksic [106]            |
| Atheris squamigera              | Green bush viper      | Africa        | TLE | aPTT, fibrinogen | Fibrinogen | Mebs [107]              |
Antivenoms are not without risk because administration of foreign proteins in the antivenoms can cause systemic hypersensitivity reactions (SHR) [47]. Early SHR include skin-only SHR, and anaphylaxis and severe anaphylaxis have been reported. Delayed reactions can also occur, and are referred to as serum sickness.

Clinical studies of antivenom

Our literature review did not identify any placebo randomised control trials of snake antivenom for VICC. There were 25 randomised comparative trials [24,48–71] of antivenom for VICC, which compared two different antivenoms (ten studies), three different antivenoms (four studies), two or three different doses or repeat doses of antivenom (five studies), heparin treatment and antivenom (five studies), and intravenous immunoglobulin treatment and antivenom (one study) (Table 2). There were a further 13 studies [8,9,20–22,72–79] which compared two groups in which there was no randomisation, including studies with historical controls (Table 3). There have been numerous observational studies of patients with VICC given antivenom, but with no comparison group.

Unfortunately there were major design issues with most of the randomised controlled trials, including lack of definition of a primary outcome or post-hoc definition of the primary outcome, no information on allocation concealment, no information on randomisation, no information on antivenom dose, or varying doses given to patients, and all but two studies [48,66] were underpowered with no sample size calculation (Table 2). The primary assessment of coagulopathy in these studies varied with different whole blood clotting tests and times (12, 15, 20, or 30 minutes) and measurement of the PT, aPTT, fibrin degradation products (FDP), D-Dimer, or fibrinogen, making comparison between studies difficult and reliability of the WBCT outcomes questionable. Many of the studies used a restoration of “coagulable blood” based on the WBCT as the major outcome, which is problematic because the reliability of WBCT20 for VICC has been recently questioned [16].

The greatest limitation of the randomised controlled trials was the absence of placebo controlled trials, so none of the trials could effectively address the question as to whether antivenom was beneficial in treating VICC. In nine of 14 studies, the authors concluded equal effectiveness of two or three antivenoms, and four of five studies of different doses or dosing regimens concluded equal effectiveness. The commonest interpretation of these studies is that antivenoms are equally effective. However, these studies actually provide no evidence for antivenom effectiveness and can be interpreted as two antivenoms being equally ineffective. All that can be concluded from these studies is that using any one of the two or three antivenoms is similarly effective.

In five of the 14 studies comparing different antivenoms, the authors concluded that one antivenom was superior to the other(s). However, on reviewing these studies, there were problems with study design or dose was confounded with antivenom type (i.e., the antivenom was less effective because an insufficient dose was given [49,68,69]). One of the better clinical trials of antivenom for VICC was the randomised comparative trial of EchiiTAB Plus equine antivenom and EchiiTAB G ovine antivenom for Echis ocellatus envenoming, which concluded that EchiiTAB Plus was slightly more effective than the other [48]. However, this study was designed as a non-inferiority study, and therefore the authors can only conclude that neither antivenom was inferior to the other, based on the primary outcome. It is incorrect to then use a

---

Table 1. Cont.

| Snake species | Common name | Distribution | Procoagulant Toxins | VICC Testing | Factor Deficiencies | References |
|---------------|-------------|--------------|---------------------|--------------|---------------------|------------|
| *Atheris chlorochis* | Western bush viper | Africa | TLE | PT, aPTT, fibrinogen | Fibrinogen | Top [108] |
| *Atheris nitschei* | Great lakes bush viper | Africa | TLE | PT, aPTT, fibrinogen, D-dimer | Fibrinogen | Hatten [109] |
| *Cerastes cerastes* | Saharan horned viper | Africa/Middle East | TLE | PT, aPTT, fibrinogen, D-dimer, factor V | Fibrinogen, FV | Lifshitz [110], Schneemann [111] |
| *Cerastes vipera* | Sahara sand viper | Africa/Middle East | TLE (cerastobin) | PT, aPTT, fibrinogen, D-dimer | Fibrinogen | Lifshitz [112] |
| *Proatheris supercilias* | Lowland viper | Africa | TLE | PT, aPTT, fibrinogen, D-dimer | Fibrinogen | Valenta [113] |
| *Bitis arietans* | African puff adders | Africa | TLE | Fibrinogen, PT, clotting factor studies | Fibrinogen | Jennings [114], Warrell [115], Lavonas [116] |
| *Bitis gabonica* | Gaboon viper | Africa | TLE (Gabonase) | Fibrinogen, PT, clotting factor studies | Fibrinogen | McNally [117] |
| *Echis coloratus* | Painted carpet viper | Africa | PTA | Fibrinogen, FDP, PT | Fibrinogen, FII, FV, FVIII | Parath [118], Mann [73] |
| *Echis ocellatus* | West African carpet viper | Africa | PTA | WBCT20, fibrinogen, clotting factor studies | Fibrinogen, FII, FV, FVIII | Warrell [8] |
| *Echis pyramidum* | Northeast African carpet viper | Africa | PTA | Fibrinogen, PT, clotting factor studies | Fibrinogen, FII, FV, FVIII | Mion [22], Gillissen [119] |
| *Dispholidus typus* | Boomslang | Africa | SWMP* | PT, aPTT, fibrinogen, FDP, thromboelastography | Fibrinogen | Atchison [5] |

aPTT – activated partial thromboplastin time, CT – clotting time, VCT – venous clotting time, FDP – fibrinogen degradation products, PLA2 – phospholipase A2, PT – prothrombin time, TLE – thrombin like enzymes, WBCT – whole blood clotting time, WBCT20 – 20 minutes whole blood clotting time, FII – factor II, FV – factor V, FX – factor X, FDP – fibrinogen degradation products; PTA – prothrombin activator; SWMP – snake venom metalloproteinase; NR – not reported; * A SWMP has been isolated from *D. typus* venom but its function (i.e., PTA activator, TLE) is unclear and only fibrinogen has been measured in patients.
one-sided p-value to suggest that one antivenom was superior to the other. Any conclusion on positive secondary outcomes is also questionable in a non-inferiority trial design. The study by Ariaranee et al., in 2001, concluded that Haffkine antivenom was more effective than Polonga TAb and that a larger dose of Polonga TAb was required [49]. They based this on only 74% of patients having coagulable blood 6 hours after Haffkine antivenom compared to 41% after Polonga Tab. However, 12 hours after antivenom, 95% of patients receiving Haffkine antivenom had coagulable blood compared to 86% receiving Polonga Tab, which was unlikely to be significant. The authors did not define a primary outcome, so the study can be interpreted differently based on whether a 6-hour or 12-hour outcome is used. The study by Smalligan et al. also concluded that one antivenom was more effective, but the study was underpowered (210 recruited versus 300 required for the sample size) and the result was not significant (p = 0.054) for the primary outcome at 6 hours if only patients given the standard initial dose were included (the outcome that the sample size appeared to be based on) [66]. Warrell et al., in 1974, compared S.A.I.M.R. antivenom and Behringwerke antivenom, but their outcomes included the dose of antivenom required and the proportion with coagulation restored. The study showed that larger amounts of Behringwerke antivenom were required, and not necessarily that it was less effective [68]. Warrell et al., in 1980, conclude in another underpowered study of 14 patients with no clearly defined primary outcome that Behringwerke antivenom was unreliable [69]. The trial was too small to show any significant difference between the two antivenoms.

In contrast to the randomised controlled trials, some non-randomised comparative studies do provide evidence for and against the effectiveness of antivenom for VICC. A number of Australian studies and one study of Papuan taipan bites found that antivenom does not prevent or speed the recovery of VICC in Australian elapid envenoming [3,9]. This was supported by computer modelling of the coagulation pathway that showed that antivenom needed to be given almost immediately to prevent VICC in Papuan taipan and Australian elapids [44,45]. One Australian study found that early (<6 hours after the bite) and late (>6 hours after the bite) administration of antivenom resulted in the same recovery rate of VICC with 3% and 33% recovering to an INR of 2 or less after 6 and 12 hours for early antivenom, compared to 3% and 27% for late antivenom [9]. Trevett et al. also showed that early antivenom (<4 hours) versus late antivenom (>4 hours) in Papuan taipan did not result in a more rapid

![Figure 1. Diagram of the clotting pathway showing the major clotting factors (blue) and their role in the activation of the pathway and clot formation. The four major groups of snake toxins that activated the clotting pathway are in green and the intermediate or incomplete products they form are indicated in dark red. There are four major types of prothrombin activators, which either convert thrombin to form the catalytically active meizothrombin (Group A and B) or to thrombin (Group C and D). doi:10.1371/journal.pntd.0003220.g001](image)
Table 2. Summary of the randomised comparative trials of treatment for VICC, including antivenom and heparin with details of study size, design, and outcomes.

| Study               | Number in each arm | Snake species         | Trial Arms | Blinded | Randomisation method | Allocation concealed | AV dose defined | Primary outcome | VICC measures | Conclusion |
|---------------------|--------------------|-----------------------|------------|---------|----------------------|----------------------|----------------|----------------|---------------|------------|
| Abubakar, 2010      | 194/206            | Echis ocellatus       | 2 AV       | Yes     | Yes                  | Good                 | Yes            | Yes            | WBCT20        | No difference between antivenoms (neither inferior) |
| Ariaratnam, 2001    | 23/20              | Daboia russelli       | 2 AV       | No      | Yes                  | Good                 | Yes            | No             | WBCT20        | No difference but multiple outcomes |
| Meyer, 1997         | 22/17              | E. ocellatus          | 2 AV       | No      | Yes                  | Nil                  | Yes            | No             | WBCT20        | No difference in restoration of clotting function |
| Otero, 1999         | 25/28              | Bothrops Parthidium sp. | 2 AV       | Yes     | Nil                  | Nil                  | No Varied*     | WBCT15/30     | No difference for either outcome |
| Otero, 1996         | 20/19              | B. atrox             | 2 AV       | Yes     | Nil                  | Good                 | Yes Varied*    | No            | WBCT15/30     | No difference but no clearly defined outcomes |
| Otero, 2006         | 34/33              | B. asper             | 2 AV       | Yes     | Nil                  | Good                 | Yes Varied*    | No            | WBCT20, fibrinogen | No difference but no outcomes and variable dosing |
| Otero-Patino, 2012  | 38/34              | B. asper             | 2 AV       | Yes     | Nil                  | Good                 | Yes Varied*    | No            | WBCT 20, fibrinogen | No difference |
| Pardal, 2004        | 38/36              | Bothrops Lachesis    | 2 AV       | Yes     | Nil                  | Good                 | Unclear        | No            | WBCT20, fibrinogen, D-dimer | No difference |
| Warrell, 1974       | 23/23              | E. ocellatus         | 2 AV       | No      | Nil                  | Nil                  | Yes Varied*    | No            | WBCT20, fibrinogen | Unclear difference in outcomes. Dose and AV confounded. |
| Warrell, 1980       | 7/7                | E. ocellatus         | 2 AV       | No      | Nil                  | Nil                  | Yes Varied*    | No            | WBCT20, fibrinogen, factor II, X, XIII | Study too small for any conclusion |
| Cardoso, 1993       | 39/41/41           | B. jararaca          | 3 AV       | Yes     | Nil                  | Nil                  | Yes Varied*    | No            | WBCT20, fibrinogen, D-dimer | Similar effectiveness of all three antivenoms |
| Otero-Patino, 1998  | 30/27/22           | Bothrops             | 3 AV       | Partial | Partial             | Nil                  | Yes Varied*    | No            | WBCT30, fibrinogen | Similar effectiveness of all three antivenoms |
| Smalligan, 2007     | 82/87/41           | Bothrops Lachesis    | 3 AV       | Yes     | Yes                  | Good                 | Yes Varied*    | Proportion with clotting blood at 6 hr | WBCT 20 | No statistically significant difference in the primary outcome or 24-hour outcome |
| Warrell et al., 1986| 15/15/16           | C. rhodostoma       | 3 AV       | No      | Nil                  | Nil                  | Yes Varied*    | No            | WBCT20, fibrinogen | Equally effective based on outcomes of restoration of coagulation |
| Dart, 2001          | 16/15              | North American Crotalid | 2 doses    | No      | Yes                  | Good                 | Yes           | Yes     | Fibrinogen, PT | Both dosing regimens were equally effective |
| Jorge, 1995         | 88/82              | Bothrops jararaca    | 4 vs. 2 vials | Yes     | Yes                  | Nil                  | Yes           | No     | WBCT10/30, fibrinogen, FDP | Both dosing regimens were equally effective |
| Karnchanachetanee, 1994 | 13/11             | D. russelli         | Low vs. high dose | No      | Nil                  | Nil                  | Yes           | No     | WBCT20 | No difference but no clear information on clotting outcomes |
| Study                  | Number in each arm | Snake species | Trial Arms                  | Blinded | Randomisation method      | Allocation concealed | AV dose defined | Primary outcome | VICC measures | Conclusion†                              |
|------------------------|--------------------|---------------|-----------------------------|---------|---------------------------|----------------------|----------------|----------------|--------------|-----------------------------------------|
| Paul, 2004             | 50/50              | *D. russellii* E. carinatus | 6 vs. 12 vials AV          | No      | Nil                        | Nil                  | Yes            | No             | WBC time, PT   | No difference                           |
| Thomas and Jacob, 1985 | 26/27              | Probably E. carinatus D. russellii | High vs. low dose          | No      | Nil                        | Nil                  | Yes            | No             | WBCT15        | No difference. Unusual dosing regimens. |
| Myint-Lwin, 1989       | 14/14              | *D. russellii* | AV vs. heparin+AV          | No      | Nil                        | Nil                  | Yes            | No             | fibrinogen, factor V, X                 | No difference with the addition of heparin |
| Paul, 2003             | 57/65              | *D. russellii* | AV vs. heparin+AV          | No      | Nil                        | Nil                  | Yes            | No             | WBCT30, PT, fibrinogen                 | No difference with the addition of heparin |
| Paul, 2007             | 40/40              | Probably *D. russellii* E. carinatus | AV vs. deltaparin+AV       | No      | Nil                        | Nil                  | Yes            | No             | WBCT30, PT, fibrinogen                 | No difference with the addition of deltaparin |
| Shah, 1986             | 25/25              | *E. carinatus* | AV vs. heparin+AV          | No      | Nil                        | Nil                  | Yes            | No             | Undefined clotting time, PT, fibrinogen | More rapid improvement in haematological parameters |
| Warrell, 1976          | 7/7                | *E. carinatus* | AV vs. heparin+AV          | No      | Nil                        | Nil                  | Yes            | No             | WBCT20, factor V, VIII, II             | No difference with the addition of heparin |
| Sellahewa, 1994        | 8/7                | Probably *D. russellii* E. carinatus | AV vs. IVIG+AV             | No      | Partial                   | Nil                  | Yes            | No             | WBCT12        | No statistically significant differences and patients were given further antivenom |

* Varied based on the clinical assessment of the severity on admission;
† May differ from the author’s conclusion, see text. Abbreviations: AV – antivenom; WBCT20 – 20-minute whole blood clotting test (or 12, 15, or 30-minute); WBC time – whole blood clotting time; IVIG – intravenous immunoglobulin; PT – prothrombin time.

doi:10.1371/journal.pntd.0003220.t002
Table 3. Summary of the non-randomised studies if VICC comparing two groups.

| Authors          | Type of study | N               | Snake species | Study Arms | Primary Outcome | Design Problems | VICC measures | Study conclusions¹ |
|------------------|---------------|-----------------|---------------|------------|----------------|----------------|---------------|---------------------|
| Bregani, 2006   | Prospective (comparison over time) | 130/98/60       | E. ocellatus  | 3 AV       | No             | Multiple outcomes without correction for multiple testing | WBCT30       | Sii Polyvalent is not effective compared to two other antivenoms. |
| Warrell, 1977   | Observational | 48/65/4         | E. ocellatus  | 3 AV       | No             | Unbalanced groups, patients re-treated with different antivenom | WBCT20       | Suggests that one antivenom was inferior. |
| Abubakar, 2010  | Dose finding study | 24              | E. ocellatus  | 3 AV       | Yes            | Nil major       | WBCT20       | Established the dose for two antivenoms for a clinical trial |
| Visser, 2008    | Prospective   | 278/48/66       | E. ocellatus  | 2 AV       | No             | Only 114 had WBCT20 done, and not all positive. Multiple outcomes. | WBCT20       | One antivenom was superior to the other based on death rate and antivenom dose |
| Isbister, 2009  | Prospective cohort | 112/29         | Australian elapids | Early (<6 h) vs. late (≥6 h) AV; [AV vs AV+FFP] | Yes            | Primary analysis was a time to event analysis, secondary analysis compared late vs. early | INR         | No difference between early and late AV group on VICC recovery. More rapid recovery with FFP. |
| Suchithra, 2008 | Prospective cohort | 142/127 [102/25] | Probably D. russelli, E. arinatus | Early (<6 h) vs. late (≥6 h) AV | No             | Subgroup analysis. Error in comparison of early and late AV for WBCT – not parametric and not significant (p = 0.15) | WBCT20, PT, aPTT | No difference between early and late AV. However, incorrect statistical analysis may have missed significant difference for WBCT20. |
| Trevett, 1995   | Prospective observational study | 33/31           | O. scutellatus | Early (<4 h) vs. late (≥4 h) AV | No             | Small subgroup analysis. | WBCT20 | No difference between early and late AV in time to recovery of WBCT20. |
| Mann, 1978      | Retrospective study | 9/9             | E. coloratus  | AV vs. no AV | No             | Sample size too small. | Fibrinogen | No difference in recovery of fibrinogen with AV. |
| Mion, 2013      | Prospective observational study (47 vs. 13) | 47/13           | E. pyramidum | AV vs. no AV | No             | Multiple outcomes | Fibrinogen, aPTT, PT | Significant difference in recovery of all coagulation parameters with AV compared to no AV. |
| Brown, 2009     | Retrospective/ Prospective study (106 vs. 21) | 106/21          | Australian elapids | AV vs. no AV; FFP vs. no FFP | Yes            | Two separate studies amalgamated. | INR, aPTT, Fibrinogen | FFP given within 4 hours of antivenom is associated with a more rapid recovery of the INR. |
| Win-Aung, 1996  | Prospective, observational study | 34/82           | D. siamensis | IM AV vs IV AV | No             | IM groups less severely envenomed, multiple outcomes and unclear if all patients given IM included | WBCT20 | Authors report a significant difference (p = 0.03) but poor design and unbalanced groups suggest this may not be a significant difference. |
| Srimannarayana, 2004 | Prospective with two arms randomised | 30/30/30 | Probably D. russelli, E. arinatus | Three dose levels | No             | Randomised controlled trial but included one non-randomised arm | WBCT30 | No difference |
| Tin, 1992       | Prospective two arms | 10/10           | D. russelli  | AV vs. heparin+AV | No             | Small study with multiple outcomes | Fibrinogen factor V, X | No difference when adding heparin |

¹May differ to the author’s conclusion, see text. Abbreviations: AV – antivenom; WBCT20 – 20 minute whole blood clotting test (or 12, 15 or 30 minute); PT – prothrombin time; aPTT – activated partial thromboplastin time; INR – international normalised ratio; IM – intramuscular; IV – intravenous.
recovery of the coagulopathy [73]. These studies suggest that there is a limited role for antivenom in the treatment of VICC resulting from Australasian elapid envenoming. However, other studies have shown that antivenom can prevent other clinical effects of envenoming such as neurotoxicity and myotoxicity [75,80], so evidence of VICC and therefore envenoming remains an indication for antivenom. However, in brown snake (Pseudonaja) envenoming, where the major clinical syndrome is VICC [81], it could be argued that antivenom does not improve outcomes, and it might be ethical to undertake a placebo controlled trial of antivenom.

Different to Australian antivenom, studies of Echis species have demonstrated an important role for antivenom in the treatment of VICC, because antivenom greatly shortens the duration of the coagulopathy. A recent study of Echis envenoming by Mion et al. showed that there was a much more rapid recovery of the PT, aPTT, and fibrinogen levels in patients given antivenom compared to those not treated [22]. The mean recovery times to fibrinogen >1 g/l was 7.5 days versus 40 hours; to a PT >50% was 5.8 days versus 25 hours, and to an aPTT <1.5 times normal was 4.7 days versus 9 hours, for untreated and antivenom treated patients respectively [22]. This supports earlier work that found the mortality from Echis envenoming was reduced in patients treated with specific antivenoms in Nigeria and the time to the restoration of clotting was much more rapid [8]. The study by Visser et al. reports an increased mortality for patients envenomed by E. ocellatus given Asna Antivenom C (Bharat Serum and Vaccines Ltd.) compared to FAV-Afrique (Aventis-Pasteur) and significantly more doses required until the WBCT20 normalised [76]. The failure of Indian antivenom is likely due to the fact that a different Echis spp. is used to produce it. There is therefore sufficient evidence from non-randomised studies that doing a placebo controlled trial would be considered unethical.

One study investigated whether the time of antivenom post-bite affected the time to recovery of the coagulopathy in Russell’s viper and carpet vipers (E. carinatus) in India [74]. The study reported that early antivenom (<6 hours after bite) compared to late antivenom (>6 hours) resulted in a more rapid recovery of the WBCT20, but not the time to recovery of standard coagulation studies (INR, aPTT). This result is difficult to interpret because it included two snake types with different types of procoagulant toxins and did not clearly define outcomes a priori. In addition, there is an error in the statistical analysis because comparison of the values reported in Table 4 in [74] does not give a significant difference in recovery of the WBCT20 between early and late antivenom administration.

The failure of antivenom for VICC in Australia and success of antivenom for VICC from Echis spp. in Africa demonstrates that studies of one snake (and therefore one procoagulant toxin) cannot be generalised to other snakes. Studies are required for each major group of snakes or toxins in different parts of the world, although understanding the mechanisms of the procoagulant toxins should inform empirical studies of different antivenoms. The prothrombin activators in Australasian elapids (Group C and D) [4] are similar to the prothrombinase complex in humans and therefore likely to be removed rapidly by pathways that eliminate human prothrombinase. However, the prothrombin activators in the venoms of Echis spp. (Group A and B) are metalloproteinases, which differ from the human clotting factors, and therefore are unlikely to be removed by normal elimination pathways.

The study by Win-Aung et al. reported the effectiveness of intramuscular antivenom and is the only study of intramuscular antivenom [77]. This finding is not consistent with pharmacokinetic studies of intramuscular antivenom, which suggest very slow and delayed absorption [82]. The study by Win-Aung did not have an appropriate control group, which was clearly shown by the fact that “test” patients had significantly lower venom concentrations (<0.001) than the control patients and so were more mildly envenomed. Considering the statistical significance in the number of patients with coagulopathy between groups was p = 0.03, it is likely that this is accounted for by the “test” group being less severely envenomed. Another concern with the study is that the authors do not report how many patients actually got intramuscular antivenom; they only included those cases in which venom was detected in blood [77]. Contrary to the authors’ conclusions this study does not support the effectiveness of intramuscular antivenom, and this route of administration should not be used.

The remaining non-randomised studies of antivenom for VICC were of poor quality (Table 3). Bregani et al. undertook a study of three different antivenoms for Echis in Africa and suggested that one was ineffective and was associated with a higher mortality and slower return of clotting function [20]. However, the study compared three groups and multiple outcomes without correcting

---

**Key Learning Points**

- Venom-induced consumption coagulopathy (VICC) results from the activation of the clotting pathway by procoagulant snake toxins and consumption of clotting factors.
- Investigation of VICC requires laboratory-based clotting studies until accurate and cheap bedside tests are available.
- There are no placebo controlled trials of antivenom, and effectiveness is not supported by numerous clinical trials comparing antivenoms.
- Non-randomised observational studies with control groups suggest that antivenom may be effective for some snakes but not others.
- There is little evidence to support the use of heparin, and fresh frozen plasma is likely to be beneficial only in actively bleeding patients.

---

**Top Five Papers**

1. Isbister GK, Scorgie FE, O’Leary MA, Seldon M, Brown SG, et al. (2010) Factor deficiencies in venom-induced consumption coagulopathy resulting from Australian elapid envenomation: Australian Snakebite Project (ASP-10). J Thromb Haemost 8: 2504–2513.
2. Isbister GK (2009) Procoagulant snake toxins: laboratory studies, diagnosis, and understanding snakebite coagulopathy. Semin Thromb Hemost 35: 93–103.
3. Mion G, Larreche S, Benois A, Petitjeans F, Puidupin M (2013) Hemostasis dynamics during coagulopathy resulting from Echis envenomation. Toxicon 76: 103–109.
4. Isbister GK, Duffull SB, Brown SG (2009) Failure of antivenom to improve recovery in Australian snakebite coagulopathy. QJM 102: 563–568.
5. Abubakar IS, Abubakar SB, Habib AG, Nasidi A, Durfa N, et al. (2010) Randomised controlled double-blind non-inferiority trial of two antivenoms for saw-scaled or carpet viper (Echis ocellatus) envenoming in Nigeria. PLoS Negl Trop Dis 4: e767.
for this, so not all of these differences may have been significant. Mann et al. undertook a small retrospective study of no antivenom versus antivenom for envenoming by *E. colorada*. Although it suggests the recovery in fibrinogen was similar, the study was small and there was no clear definition of recovery [73]. Two studies not included in the 13 simply compared the occurrence of coagulation abnormalities in the envenomed patients and not the recovery of coagulation [23,83]. This meant that severity of envenoming was confounded with antivenom treatment, making it difficult to assess the effect of antivenom.

Another important issue is determining the effective dose of antivenom. There has been significant contention in Australia regarding the dose of antivenom. Recent studies have demonstrated that one vial of antivenom is as effective as two or more vials of antivenom for VICC resulting from snake envenoming [81]. However, it is clear from many of the studies that some antivenoms are not effective because an insufficient dose of the antivenom has been given [49,76]. It is essential that future studies do not confound dose and type of antivenom, and that the optimal dose of antivenom is determined in pre-clinical studies or small dose-finding studies prior to larger controlled trials of antivenom effectiveness.

There are numerous observational studies that report the effectiveness of antivenom, but they simply report the restoration of coagulability for a single group of patients that are all given antivenom. Clearly, further studies of antivenom for VICC are required, but conducting placebo controlled trials is challenging if not impossible due to ethical issues. Good observational studies and historical control studies will hopefully help provide better evidence for the role of antivenom in VICC from different snakes.

**Other Treatments**

**Clotting factor replacement**

VICC is characterised by low or undetectable levels of one or more clotting factors, most commonly fibrinogen. Antivenom will only stop the consumptive process so once it has been given it still takes 24 to 48 hours for full recovery of the clotting factors [3]. While the clotting factors are being re-synthesized by the liver there is a period of time during which the patient remains at risk of haemorrhage. For this reason, clotting factor replacement has been suggested as an adjunct treatment for VICC. The most commonly used factor replacement is fresh frozen plasma because it is the most widely available and contains almost all the important factors, such as fibrinogen, factor V, factor VIII, and factor X.

Clotting factor replacement for VICC is controversial because of the concern that it may worsen VICC by providing more clotting factors (substrate) for the procoagulant toxins [84,85]. However, it has been assumed that once antivenom has been given and the toxins are bound, clotting factor replacement is likely to speed the rate of recovering. Two observational studies from Australia support this [9,21] but a more recent randomised controlled trial in Australia only partly supports the use of fresh frozen plasma (FFP) and raises concern about the early use of FFP [86].

The recent randomised controlled trial of FFP for treating VICC in Australian snake envenoming shows that the administration of FFP within 4 hours of antivenom results in more rapid restoration of clotting function in the majority of patients [86]. In a study of 65 patients, 30 of 41 patients (73%) randomised to FFP had an INR of <2 six hours after antivenom compared to only six of 24 patients (25%) not given FFP (absolute difference 48%; 95% confidence interval (CI): 23%−73%; *p* = 0.0002). However, there was no difference in time to discharge and the study was too small to detect any different in major haemorrhage between FFP and no FFP. An interesting finding of the study was that non-responders in the FFP arm were given FFP significantly earlier post-bite (not post-antivenom) than those who responded to FFP (4.7 hours versus 7.3 hours; *p* = 0.002) [86]. The reason for this finding is not completely clear, but clotting factor studies done in a subgroup of patients demonstrated that those receiving early FFP had evidence of consumption after the FFP was given with increasing D-Dimer and decreasing fibrinogen. However, all these patients had received antivenom prior to the FFP, suggesting that the active clotting factors were endogenous ones activated in the initial consumptive process and not the procoagulant toxin.

Reactions to FFP are well recognised, but are relatively uncommon [87]. There were no adverse reactions in the randomised controlled trial by Isbister et al. in 2013 that could be directly attributed to the FFP. However, the study was small and uncommon complications such as transfusion-related acute lung injury (TRALI) and anaphylaxis must be considered when balancing the risk of FFP versus the benefit. The current evidence would suggest that FFP should be administered in patients with acute bleeding and is more likely to be effective if given more than 6 hours after the bite. However, there is much less evidence to support FFP in patients with VICC without active bleeding, and larger studies are required to better define this patient group. Nevertheless, in life-threatening bleeding from VICC, such as with intracranial haemorrhage, delaying the use of FFP based on these findings is not recommended.

There is far less information on other forms of factor replacement, including cryoprecipitate, prothrombinex, or single factor concentrations. It would seem theoretically useful to give cryoprecipitate to patients bitten by snakes with thrombin-like enzymes, who mainly have a fibrinogen deficiency. However, there is little evidence to support this and patients only need low levels of fibrinogen to have close-to-normal clotting function. One retrospective study included patients given cryoprecipitate, but the numbers were too small for any analysis [21].

**Heparin**

Heparin has been suggested for the treatment of VICC resulting from viper envenoming, but its use is controversial and there is little evidence to support its effectiveness. Three of five randomised comparison studies concluded that heparin and antivenom are more effective than antivenom alone [24,53,61,63,65]. There was one non-randomised study that concluded no benefit [78]. However, all these studies were poorly designed with poor definition of primary outcomes, blinded allocation, and clotting tests.

Shah et al. reported in 1986 that the addition of heparin resulted in a great proportion of patients with normalised haematological parameters of four different time points compared to antivenom alone [65]. This result needs to be interpreted with caution because it is unclear which parameters had to normalise and multiple time points were used [65]. Paul et al. reported two studies investigating the effect of heparin that showed no significant difference despite the conclusion heparin was effective. The first study showed no statistical benefit of the addition of heparin that showed no significant difference despite the conclusion heparin was effective. The authors incorrectly suggest that heparin resulted in an improved morbidity and mortality, based on very small and non-significant differences in some outcomes [61]. In the second, smaller study the authors found no significant difference between the antivenom and antivenom with heparin on all outcomes [63].
The three trials that concluded heparin was not effective were all too small \(N = 14, 20, 20\) to detect any but the largest difference between treatments, due to type II errors. In addition, all these studies had poorly defined outcomes, including no pre-specified primary outcome \[24,33,78\]. There is insufficient evidence to support the use of heparin, but well-designed, large studies are required to confirm that there is no effect.

**Conclusions**

VICC is one of the most important clinical syndromes that occurs with snake envenoming and it includes a broad range of factor deficiencies depending on the particular procoagulant toxin in the snake venom. Diagnosis and monitoring of the coagulopathy is problematic, particularly in resource-poor countries where the only clotting test available is the whole blood clotting test. Research is required to develop more reliable cheap clotting tests to be used for the diagnosis and treatment of VICC. Antivenom is the major treatment for VICC, but there is little high-quality evidence to support its effectiveness. Observational studies have suggested that it may be highly effective for some snakes (e.g., *Echis* spp.) and ineffective for other snakes (e.g., Australasian elapids). Antivenom is not risk free and adverse reactions can be quite common and potentially severe. There is evidence to support the use of FFP in bleeding patients with VICC. There is no evidence to support the use of heparin. In all cases it is important to observe for signs of external and internal bleeding. Patients should be observed in hospital until clotting function has normalised.

**References**

1. Kasturiratne A, Wickremasinghe AR, de Silva N, Gunawardena N, Pathmeswaran A, et al. (2008) The global burden of snakebite: a literature analysis and modelling based on regional estimates of envenoming and deaths. PLoS Med 5: e220.

2. Isbister GK (2010) Snakebite doesn’t cause disseminated intravascular coagulopathy: coagulopathy and thrombotic microangiopathy in snake envenoming. Semin Thromb Hemost 36: 444–451.

3. Isbister GK, Scorgie FE, O’Leary MA, Seldom M, Brown SG, et al. (2010) Factor deficiencies in venom-induced consumption coagulopathy resulting from Australian elapid envenomation: Australian Snakebite Project (ASP-10).

4. Warrell DA, Pope HM, Prentice CR (1976) Disseminated intravascular coagulation caused by the carpet viper (Echis carinatus) trial of heparin. Br J Haematol 33: 315–342.

5. Mundo N, Remeur JP, Eddine SA, Fagot P, Rage V, et al. (1998) Clinical safety assessment of immunoreactivity of a new purified equine F(ab\(^\prime\))\(_2\)-polyvalent F(ab\(^\prime\))\(_2\)-assessment of immunoreactivity of a new purified equine F(ab\(^\prime\))\(_2\) in Nigeria. Ann Trop Med Parasitol 82: 311–313.

6. Sotelo N (2008) Review of treatment and complications in 79 children with rattlesnake bite. Clin Pediatr (Phila) 47: 463–469.

7. Heard K, O'Malley GF, Dart RC (1999) Antivenom therapy in the Americas. J Toxicol Cutan Vener Dis 11: 25–28.

8. Offerman SR, Barry JD, Schneir A, Clark RF (2003) Biphasic rattlesnake antivenom-induced thrombocytopenia. J Emerg Med 24: 299–303.

9. Lu Q, Clemetson JM, Clemetson KJ (2005) Snake venoms and hemostasis. Trans R Soc Trop Med Hyg 99: 657–662.
43. Bogarin G, Morais JF, Yamaguchi IK, Stephano MA, Marcelino JR, et al. (2008) A blinded clinical trial of two antivenoms, prepared by caprylic acid or phospholipid, for the treatment of Bothrops jararaca bites in Colombia. Toxicon 52: 1173–1182.

44. Tanos PP, Isbister GK, Lalloo DG, Kirkpatrick CM, Duffull SB (2008) A randomized, double-blind clinical trial of two antivenoms in patients bitten by Bothrops asper in Brazil. Trans R Soc Trop Med Hyg 102: 445–450.

45. Win A, Tin T, Khin Maung M, Aye K, Hla H, et al. (1996) Clinical trial of intramuscular anti-snake venom administration as a first aid measure in the field in the management of Russell’s viper bite patients. Southeast Asian J Trop Med Public Health 27: 271–277.

46. Karmacharaneratne C, Hasanovitch-Godfrey S, Sivarajah C, Tannian S, Khanam I, et al. (1994) Monospecific antivenin therapy in Russell’s viper bite. J Med Assoc Thai 77: 293–297.

47. Otero R, Gutierrez JM, Nunez V, Rohles A, Estrada R, et al. (1996) A randomized double-blind clinical trial of two antivenoms in patients bitten by Bothrops atrox in Colombia. The Regional Group on Antivenom Therapy Research (REGATHER). Trans R Soc Trop Med Hyg 90: 696–700.

48. Otero-Patino R, Cardoso JL, Higashi HG, Nunez V, Diaz A, et al. (1998) A randomized, blinded, comparative trial of one pepsin-digested and two whole IgG antivenoms for Bothrops snake bites in Uraba, Colombia. The Regional Group on Antivenom Therapy Research (REGATHER). Am J Trop Med Hyg 58: 183–189.

49. Otero R, Gutierrez JM, Rojas G, Nunez V, Diaz A, et al. (1999) A randomized blinded clinical trial of two antivenoms, prepared by caprylic acid or ammonium sulphate fractionation of IgG, in Bothrops and Porthidium snake bites in Colombia: correlation between safety and biochemical characteristics of antivenoms. Toxicon 37: 895–908.

50. Otero R, Leon G, Gutierrez JM, Rojas G, Toro MF, et al. (2006) Efficacy and safety of two IgG polyvalent antivenoms, refined by caprylic acid fractionation with or without beta-propiolactone, in the treatment of Bothrops asper bites in Colombia. Trans R Soc Trop Med Hyg 100: 1173–1182.

51. Otero-Patino R, Segura A, Herrera M, Angulo Y, Leon G, et al. (2012) Comparative study of the efficacy and safety of two polyclonal caprylic acid fractionated [IgG and Fab’2] antivenoms, in Bothrops asper bites in Colombia. Toxicon 59: 344–355.

52. Patural PP, Souza SM, Monteiro MR, Fan HW, Cardoso JL, et al. (2004) Clinical trial of two antivenoms for the treatment of Bothrops and Lachesis bites in the north eastern Amazon region of Brazil. Trans R Soc Trop Med Hyg 98: 28–42.

53. Paul V, Prahlah KA, Eraldi J, Francis S, Lewis F (2003) Trial of heparin in the treatment of snake bites. J Assoc Physicians India 51: 661–666.

54. Paul V, Prathiba S, Pratibha KA, Eraldi J, Francis S, et al. (2008) High-dose anti-snake venom versus low-dose anti-snake venom in the treatment of poisonous snake bites—a critical study. J Assoc Physicians India 52: 14–17.
91. Budzynski AZ, Pandya BV, Rubin RN, Brizuela BS, Soszka T, et al. (1984) Alterations of the blood coagulation system after accidental human inoculation by Bothrops jararaca venom. Braz J Med Biol Res 19: 199–204.

92. Barrantes A, Solis V, Bolanos R (1985) Alterations in the coagulation mechanisms of patients bitten by Bothrops asper (Terciopelo). Toxicon 23: 399–407.

93. Kamiguti AS, Matsunaga S, Spir M, Sano-Martins IS, Nahas L (1986) Fibrinogenolytic afibrinogenemia after envenomation by western diamondback rattlesnake (Crotalus atrox). Blood 63: 1–14.

94. Ketsueki 24: 256–262.

95. Kamiguti AS, Cardoso JL (1989) Haemostatic disturbances caused by the venoms of South American snakes. Toxicon 27: 955–963.

96. Kamiguti AS, Matsunaga S, Spip M, Sano-Martins IS, Nahas L (1986) Alterations of the blood coagulation system after accidental human inoculation by Bothrops jararaca venom. Braz J Med Biol Res 19: 199–204.

97. Sano-Martins IS, Tomy SC, Campolina D, Dias MB, de Castro SC, et al. (2001) Coagulopathy following lethal and non-lethal envenoming of humans by the South American rattlesnake (Crotalus durissus) in Brazil. QJM 94: 551–559.

98. Kamiguti AS, Cardoso JL (1989) Haemostatic changes caused by the venoms of South American snakes. Toxicon 27: 955–963.

99. Budleynski AZ, Pandya BV, Rubin RN, Brizuela BS, Soszka T, et al. (1984) Fibrinogenolytic afibrinogenemia after envenomation by western diamondback rattlesnake (Crotalus atrox). Blood 63: 1–14.

100. Kitchens C, Eskin T (2008) Fatality in a case of envenomation by Crotalus adamanteus initially successfully treated with polyvalent ovine antivenom followed by recurrence of defibrinogenation syndrome. J Med Toxicol 4: 180–183.

101. Hardy DL, Jeter M, Corrigan JJ Jr (1982) Envenomation by the northern blacktail rattlesnake (Crotalus molossus molossus): report of two cases and the in vitro effects of the venom on fibrinolysis and platelet aggregation. Toxicon 20: 487–493.

102. Haisha U, Rosenbach LM, Rockwell D, Lewis JH (1975) DfiC-like syndrome after envenomation by the snake, Crotalus horridus horridus. N Engl J Med 292: 503–507.

103. Bush SP, Green SM, Moynihan JA, Hayes WK, Cardwell MD (2002) Crotalidae polyvalent immune Fab (ovine) antivenom is efficacious for envenomations by Southern Pacific rattlesnakes (Crotalus helleri). Ann Emerg Med 40: 619–624.

104. Boels D, Hamel JF, Bertaudeau Deguigne M, Harry P (2012) European viper envenomings: Assessment of Viperfav and other symptomatic treatments. Clin Toxicol (Phila) 50: 118–129.

105. Petite J (2005) Viper bites: treat or ignore? Review of a series of 99 patients bitten by Vipera aspis in an alpine Swiss area. Swiss Med Wkly 135: 618–625.

106. Luksic B, Calic V, Stricicic I, Breiz I, Poljak NK, et al. (2010) Infant death after nose-horned viper (Vipera ammodytes ammodytes) bite in Croatia: A case report. Toxicol 36: 1506–1509.

107. Mebs D, Holada K, Kornalik F, Simak J, Vankova H, et al. (1998) Severe coagulopathy after a bite of a green bush viper (Atheris squamigera): case report and biochemical analysis of the venom. Toxicol 36: 1333–1340.

108. Top LJ, Tulleken JE, Liptonberg JJ, Meertens JH, van der Werf TS, et al. (2006) Serious envenomation after a snakebite by a Western bush viper (Atheris chlorechis) in the Netherlands: a case report. Neth J Med 64: 133–136.

109. Hatten BW, Busso A, French LK, Hendrickson RG, Horowitz BZ (2013) Envenomation by the Great Lakes Bush Viper (Atheris nitschei). Clin Toxicol (Phila) 51: 114–116.

110. Lillhitz M, Kastel H, Harman-Boehm I (2002) Cerastes cerastes envenomation in an 18 year old female: a case report. Toxicol 40: 1227–1229.

111. Schuerman M, Cathomas R, Laidlaw ST, El Nahas AM, Theakston RD, et al. (2004) Life-threatening envenomening by the Saharan horned viper (Cerastes cerastes) causing micro-angiopathic haemolysis, coagulopathy and acute renal failure: clinical cases and review. QJM 97: 717–727.

112. Lifshitz M, Kapelushnik J, Ben-Harosh M, Sofer S (2000) Disseminated intravascular coagulation after cerastes viper envenomation in a 3-year-old child: a case report. Toxicol 38: 1593–1598.

113. Valenta J, Stach Z, Fricova D, Zak J, Balik M (2008) Envenoming by the viperid snake Pseudechis prasina: a case report. Toxicol 52: 392–394.

114. Jennings BR, Spearman CW, Kirsch RE, Shepherd EG (1999) A novel high molecular weight fibrinogenase from the venom of Bitsis arietans. Biochim Biophys Acta 1427: 82–91.

115. Mowbray DA, Ormerod DD, Davidson NM (1975) Bites by puff adder (Bitis arietans) in Nigeria, and value of antivenom. Br Med J 4: 697–700.

116. Lavonas EJ, Tomaszewski CA, Ford MD, Rouse AM, Kerns WP 2nd (2002) Severe puff adder (Bitis arietans) envenomation with coagulopathy. J Toxicol Clin Toxicol 40: 911–918.

117. Mebs D, Holada K, Kornalik F, Simak J, Vankova H, et al. (1998) Severe coagulopathy after a bite of a green bush viper (Atheris squamigera): case report and biochemical analysis of the venom. Toxicol 36: 1333–1340.

118. Porath A, Gilon D, Schulchynska-Castel H, Shalev O, Keynan A, et al. (1992) Arboreal green pit vipers (genus Trimeresurus) of South-East Asia: bites and biochemical analysis of the venom. Toxicon 30: 25–32.

119. Bublitz M, Hildebrandt H, Jahns-Uhlig R, Krug D, Kiefer RC, et al. (2010) Infant death after nose-horned viper (Vipera ammodytes ammodytes) bite in Croatia: A case report. Toxicol 36: 1506–1509.